PT  - JOURNAL ARTICLE
AU  - Céline Mascaux
AU  - Pascale Tomasini
AU  - Laurent Greillier
AU  - Fabrice Barlesi
TI  - Personalised medicine for nonsmall cell lung cancer
AID  - 10.1183/16000617.0066-2017
DP  - 2017 Dec 31
TA  - European Respiratory Review
PG  - 170066
VI  - 26
IP  - 146
4099  - http://err.ersjournals.com/content/26/146/170066.short
4100  - http://err.ersjournals.com/content/26/146/170066.full
SO  - EUROPEAN RESPIRATORY REVIEW2017 Dec 31; 26
AB  - After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence of specific biomarkers which indicate sensitivity to corresponding targeted therapies and/or lower toxicity risk, such that patients will have the greatest chance of deriving benefit from the treatments. Here, we review personalised medicine for nonsmall cell lung cancer.Herein we review personalised medicine for nonsmall cell lung cancer http://ow.ly/LiiI30fXUlJ